CommercialPrior AuthMedium impact
State and School Employees' Health Insurance Plan - Immune Thrombocytopenia
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi State and School Employees' Health Insurance Plan has established new prior authorization requirements for immune thrombocytopenia (ITP) treatments, including specific IVIG products and rituximab biosimilars. The policy requires strict platelet count thresholds, failed corticosteroid trials, and hematologist consultation for coverage approval.
Action Required
Before January 1, 2025: Billing team must implement prior authorization requirements for ITP treatments including Gammaked, Gamunex-C, Privigen, Octagam, and rituximab biosimilars. Update system to verify platelet counts (<30 x 109/L or <50 x 109/L with bleeding), document corticosteroid failure after 4-6 weeks, and confirm hematologist consultation. Claims for these medications without prior approval will be denied as not medically necessary.